MétaCan
Menu
← Back to cohort
Record W4206580270 · doi:10.21203/rs.3.rs-268937/v1

Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): Study protocol for an international, multicenter, randomized, open-label trial

2021· preprint· en· W4206580270 on OpenAlexafffund
Philippe Bégin, Jeannie Callum, Nancy M. Heddle, Richard J. Cook, Michelle P. Zeller, Alan Tinmouth, Dean Fergusson, Melissa M. Cushing, Marshall J. Glesby, Michaël Chassé, Dana V. Devine, Nancy Robitaille, Renée Bazin, Nadine Shehata, Andrés Finzi, Allison McGeer, Damon C. Scales, Lisa Schwartz, Alexis F. Turgeon, Ryan Zarychanski, Nick Daneman, Richard Carl, Luiz Amorim, Caroline Gabe, Martin Ellis, Erin Jamula, Julie Carruthers, Joanne Duncan, Kayla J. Lucier, Chantal Armali, Amie Kron, Dimpy Modi, Marie‐Christine Auclair, Meda Avram, Donald M. Arnold

Bibliographic record

VenueResearch Square · 2021
Typepreprint
Languageen
FieldMedicine
TopicCOVID-19 Clinical Research Studies
Canadian institutionsCentre Hospitalier Universitaire Sainte-JustineSunnybrook Health Science CentreCanadian Blood ServicesUniversity of ManitobaHéma-QuébecHealth Sciences CentreOttawa HospitalUniversity of OttawaUniversity of WaterlooMcMaster UniversityUniversity of TorontoUniversité LavalUniversité de Montréal
FundersCanadian Institutes of Health ResearchHealth Sciences Centre FoundationMinistry of Health, SaskatchewanUniversity of AlbertaUniversity of TorontoMcMaster University
KeywordsCoronavirus disease 2019 (COVID-19)MedicineConvalescent plasmaRandomized controlled trialSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Protocol (science)2019-20 coronavirus outbreakOpen labelRespiratory illnessPandemicMulticenter studyRespiratory systemIntensive care medicineBetacoronavirusVirologyInternal medicineInfectious disease (medical specialty)PathologyOutbreakDiseaseAlternative medicine

Abstract

fetched live from OpenAlex

Abstract Background: Convalescent plasma has been used for numerous viral diseases including influenza, severe acute respiratory syndrome, Middle East respiratory syndrome and Ebola virus; however, evidence to support its use is weak. SARS-CoV-2 is a novel coronavirus responsible for the 2019 global pandemic of COVID-19 community acquired pneumonia. We have undertaken a randomized controlled trial to assess the efficacy and safety of COVID-19 convalescent plasma (CCP) in patients with SARS-CoV-2 infection.Methods: CONCOR-1 is an open-label, multicenter, randomized trial. Inclusion criteria include: patients >16 years; admitted to hospital with COVID-19 infection; receiving supplemental oxygen for respiratory complications of COVID-19; and, availability of blood group compatible CCP. Exclusion criteria are: onset of respiratory symptoms more than 12 days prior to randomization; intubated or planned for intubation; and previous severe reactions to plasma. Consenting patients will be randomized 2:1 to receive either approximately 500 mL of CCP or standard of care. CCP will be collected from donors who have recovered from COVID-19 and who have detectable anti-SARS-CoV-2 antibodies quantified serologically. The primary outcome is intubation or death at Day 30. Secondary outcomes include ventilator free days, length of stay in intensive care or hospital, transfusion reactions, serious adverse events, and reduction in SARS-CoV-2 viral load. Exploratory analyses include patients who received CCP containing high titre antibodies. A sample size of 1200 patients gives 80% power to detect a 25% relative risk reduction assuming a 30% baseline risk of intubation or death at 30 days (two-sided test; α =0.05). An interim analysis and sample size re-estimation will be done by an unblinded independent biostatistician after primary outcome data are available for 50% of the target recruitment (n= 600). Discussion: This trial will determine whether CCP will reduce intubation or death non-intubated adults with COVID-19. The trial will also provide information on the role of and thresholds for SARS-CoV-2 antibody titers and neutralization assays for donor qualification.Trial registration: Clinicaltrials.gov NCT04348656; registered 16 April 2020; https://clinicaltrials.gov/ct2/show/NCT04348656?term=NCT04348656&draw=2&rank=1

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.024
metaresearch head score (Gemma)0.019
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Protocol · Consensus signal: Protocol
Teacher disagreement score0.057
Threshold uncertainty score0.190

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0240.019
Meta-epidemiology (narrow)0.0070.003
Meta-epidemiology (broad)0.0100.004
Bibliometrics0.0020.002
Science and technology studies0.0030.004
Scholarly communication0.0040.004
Open science0.0040.002
Research integrity0.0070.008
Insufficient payload (model declined to judge)0.0570.011

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.356
GPT teacher head0.614
Teacher spread0.258 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreProtocol

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2021
Admission routes2
Has abstractyes

Explore more

Same venueResearch Square→Same topicCOVID-19 Clinical Research Studies→French-language works237,207→